In addition, the aim of anti-PD-1/PD-L1 therapies is to prevent the interaction between PD-L1 located on the cell membrane of cancer cells and PD-1 located on the surface of T cells, thereby restoring the anti-tumor functions of T cells. The gene discussed is PDCD1; the disease is neoplasm.